Lina Huerta‐Saenz

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial

Lori M. Laffel, Thomas Danne, Georgeanna J. Klingensmith et al. · The Lancet Diabetes & Endocrinology · 2023 · 98 citations · Full text

Metabolic Syndrome, Diabetes Management, Young People +11

Tap or Bottled Water: Drinking Preferences Among Urban Minority Children and Adolescents

Lina Huerta‐Saenz, Matilde Irigoyen, Jorge Benavides et al. · Journal of Community Health · 2011 · 84 citations

Substance Abuse, Substance Use, Drinking Preferences +10

The Coronavirus Disease 2019 Pandemic is Associated with a Substantial Rise in Frequency and Severity of Presentation of Youth-Onset Type 2 Diabetes

Sheela N. Magge, Risa M. Wolf, Laura Pyle et al. · The Journal of Pediatrics · 2022 · 65 citations · Full text

Youth-onset Type 2, Coronavirus Disease 2019, Diabetes Epidemiology +10

De Novo and Inherited Pathogenic Variants in KDM3B Cause Intellectual Disability, Short Stature, and Facial Dysmorphism

Illja J. Diets, Roos van der Donk, Kristina Baltrunaite et al. · The American Journal of Human Genetics · 2019 · 47 citations · Full text

Developmental Biology, Mendelian Disorder, Short Stature +9

Gender Bias in U.S. Pediatric Growth Hormone Treatment

Adda Grimberg, Lina Huerta‐Saenz, Robert W. Grundmeier et al. · Scientific Reports · 2015 · 42 citations · Full text